SOME FACTORS RELATED TO TREATMENT OUTCOMES IN PATIENTS WITH BRAIN METASTASES UNDERGOING SURGERY

Văn Thái Phạm, Huy Mạnh Bùi, Văn Khoa Nguyễn

Main Article Content

Abstract

Objective: To evaluate some factors related to treatment outcomes in patients with brain metastases undergoing surgery. Subjects and Methods: This descriptive study was conducted on 81 patients diagnosed with brain metastases and treated with surgery at the Neurosurgery Center, Viet Duc Hospital, from June 2021 to December 2022. Results: Patients with a history of cancer and a low Karnofsky performance status index had a higher risk of mortality (HR > 1), with statistically significant differences (p< 0.05). The group of patients receiving combined treatment (chemotherapy, radiotherapy, or targeted therapy) in conjunction with surgery for brain metastases had a lower mortality rate and a longer mean survival time compared to those undergoing surgery alone (36.1% vs. 82.2%; 17.2 ± 1.4 months vs. 7.5 ± 1.0 months). The differences were statistically significant (p= 0.00). Patients with controlled primary tumors had a lower mortality rate and longer mean survival compared to those with uncontrolled primary tumors (44.1% vs. 75.5%; 14.8 ± 1.5 months vs. 9.7 ± 1.3 months). This difference was statistically significant (P = 0.006). Conclusion: Karnofsky performance status, history of cancer, treatment modality (surgery alone or in combination), and primary tumor control were factors significantly associated with treatment outcomes (p< 0.05). Patients with a low Karnofsky index and a history of cancer had an increased risk of mortality. Patients who underwent combined treatment, including surgery for brain metastases and primary tumor control, had lower mortality rates and longer survival times compared to those who had surgery alone or did not achieve primary tumor control

Article Details

References

Amsbaugh MJ, Kim CS. Brain Metastasis. In: StatPearls. StatPearls Publishing; 2023. Accessed May 17, 2023. http://www.ncbi.nlm. nih. gov/ books/NBK470246/
2. NCCN Clinical Practice Guidelines in Oncology (2024). Central Nervous System Cancers, V3.2024
3. Nathoo N, Toms SA, Barnett GH, et al (2004). Metastases to the brain: current management perspectives. Expert Rev Neurother. 2004;4(4): 633-640. doi:10.1586/14737175.4.4.633
4. Eichler AF, Loeffler JS, et al (2007). Multidisciplinary management of brain metastases. The Oncologist. 2007;12(7):884-898. doi:10.1634/ theoncologist. 12-7-884
5. Vogelbaum MA, Brown PD, Messersmith H, et al (2022). Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(5):492-516. doi:10.1200/JCO.21.02314
6. Rittberg R, Banerji S, Kim JO, et al (2017). Treatment and Prevention of Brain Metastases in Small Cell Lung Cancer. Am J Clin Oncol. 2021;44(12): 629-638. doi:10.1097/COC. 0000000000000867
7. Zheng X, Mu S, Wang L, et al (2023). Factors for incidence risk and prognosis of synchronous brain metastases in pulmonary large cell carcinoma patients: a population-based study. BMC Pulm Med. 2023;23(1):12. doi:10.1186/ s12890-023-02312-y
8. Jose MR , Daniella BR, Juliete MD, et al (2018). Analysis of survival in patients with brain metastases treated surgically: Impact of age, gender, oncologic status, chemotherapy, radiotherapy, number and localization of lesions, and primary cancer site. Rev Assoc Med Bras. 2018; 64(8): 717-722. doi:10.1590/1806-9282.64.08.717
9. Jun S, Jingwei L, Lujia S, Qiuyao H , et al (2021). The number of brain metastases predicts the survival of non-small cell lung cancer patients with EGFR mutation status. Published online November 12, 2021. doi:10.1002/CNR2.1550
10. Altaf AL, Syed IA, Muhammad SS (2017). Role of surgery in brain metastases. J Pak Med Assoc. 2017; 67(8): 1299-1300.